Empagliflozin Restores the Colonic Mucous Barrier by an AMPK/SOX4‐Dependent Pathway in Glycogen Storage Disease Type Ib
Abstract
Glycogen storage disease type Ib (GSD‐Ib) is commonly associated with refractory inflammatory bowel disease (GSD‐IBD). Although the SGLT2 inhibitor empagliflozin has demonstrated remarkable clinical efficacy, its direct effects on the intestinal epithelium remain poorly understood. This study aimed to determine whether empagliflozin directly restores the impaired colonic mucus barrier and to identify the underlying molecular pathway. In terms of efficacy, we integrated clinical evaluations of GSD‐IBD patients with a novel murine model of epithelial injury induced by a defined bacterial consortium (EVS: Enterococcus, Veillonella, Streptococcus) and dextran sulfate sodium (DSS). In vitro, we employed Caco‐2 cells and intestinal organoids, combined with pharmacological inhibition of AMPK and siRNA‐mediated gene knockdown to elucidate the underlying molecular mechanisms. Clinical data indicated that empagliflozin promoted ulcer healing and enhanced mucin production in patients. In the EVS + DSS mouse model, empagliflozin treatment reduced disease severity and attenuated goblet cell depletion. We demonstrated that empagliflozin upregulates the transcription factor SOX4 in intestinal epithelial cells both in vivo and in vitro, an effect dependent on AMPK activation. Notably, siRNA knockdown of SOX4 abolished empagliflozin‐induced MUC2 upregulation. Furthermore, pharmacological inhibition of AMPK suppressed the induction of MUC2, which could be rescued by SOX4 overexpression. Our…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.